Number of Participants with Unsolicited Adverse Events;Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale;Number of Participants with Solicited Systemic Adverse Events;Duration of Solicited Systemic Adverse Events;Number of Participants with Solicited Systemic Adverse Events Considered Related to Trial Vaccine;Intensity of Unsolicited Adverse Events per the FDA Toxicity Grading Scale;Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine;Number of Participants with One or More Serious Adverse Events (SAEs);Duration of Solicited Local Adverse Events;Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale;Number of Participants with One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine;Number of Participants with Solicited Local Adverse Events;Number of Participants with One or More Adverse Events of Special Interest (AESIs);Number of Participants with One or More Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine;Number of Participants Seroconverting for SARS-CoV-2 Spike Protein Antibodies;Number of Participants Seroconverting for SARS-CoV-2 Spike Protein Antibodies;Individual SARS-CoV-2 Spike Protein-Specific Antibody Levels in Serum;Individual SARS-CoV-2 Spike Protein-Specific Antibody Levels in Serum;Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Spike Protein Antibodies;Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Spike Protein Antibodies;Number of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies;Number of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies;Individual SARS-CoV-2 Neutralizing Antibody Levels in Serum;Individual SARS-CoV-2 Neutralizing Antibody Levels in Serum;Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Neutralizing Antibodies;Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Neutralizing Antibodies

Number of Participants with Unsolicited Adverse Events;Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale;Number of Participants with Solicited Systemic Adverse Events;Duration of Solicited Systemic Adverse Events;Number of Participants with Solicited Systemic Adverse Events Considered Related to Trial Vaccine;Intensity of Unsolicited Adverse Events per the FDA Toxicity Grading Scale;Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine;Number of Participants with One or More Serious Adverse Events (SAEs);Duration of Solicited Local Adverse Events;Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale;Number of Participants with One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine;Number of Participants with Solicited Local Adverse Events;Number of Participants with One or More Adverse Events of Special Interest (AESIs);Number of Participants with One or More Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine;Number of Participants Seroconverting for SARS-CoV-2 Spike Protein Antibodies;Number of Participants Seroconverting for SARS-CoV-2 Spike Protein Antibodies;Individual SARS-CoV-2 Spike Protein-Specific Antibody Levels in Serum;Individual SARS-CoV-2 Spike Protein-Specific Antibody Levels in Serum;Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Spike Protein Antibodies;Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Spike Protein Antibodies;Number of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies;Number of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies;Individual SARS-CoV-2 Neutralizing Antibody Levels in Serum;Individual SARS-CoV-2 Neutralizing Antibody Levels in Serum;Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Neutralizing Antibodies;Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Neutralizing Antibodies